Hurlé M A, Dierssen M M, Morin-Surun M P, Oceja C, Flórez J
Department of Pharmacology and Therapeutics Faculty of Medicine, University of Cantabria, National Hospital, M. de Valdecilla, Santander, Spain.
Peptides. 1988 Jul-Aug;9(4):809-15. doi: 10.1016/0196-9781(88)90126-x.
A functional differentiation of the action of cholecystokinin octapeptide (CCK-8) on the respiratory centers was accomplished by the topical application to the ventral surface of the medulla and to the dorso-rostral pontine surface in cats. In the medulla, CCK-8S at doses ranging from 0.09 nmol to 0.88 nmol, stimulated tidal volume in a dose-dependent fashion, with minimal or no changes in frequency. The antagonist proglumide (30 nmol) inhibited specifically the action on the respiratory amplitude. In the pons, CCK-8S did not modify the respiratory activity even at the dose of 8.8 nmol. The results suggest a specific involvement of CCK-8S in the mechanisms controlling respiratory amplitude, which appear mostly restricted to the medullary level. The lack of effect of the peptide in the pons is in agreement with the absence of CCK receptors in the respiration related nuclei located at that level, as evidenced by autoradiographic studies.
通过向猫的延髓腹面和脑桥背侧-嘴侧表面局部应用八肽胆囊收缩素（CCK-8），实现了其对呼吸中枢作用的功能分化。在延髓中，剂量为0.09纳摩尔至0.88纳摩尔的CCK-8S以剂量依赖性方式刺激潮气量，频率变化最小或无变化。拮抗剂丙谷胺（30纳摩尔）特异性抑制对呼吸幅度的作用。在脑桥中，即使剂量为8.8纳摩尔，CCK-8S也不改变呼吸活动。结果表明CCK-8S特异性参与控制呼吸幅度的机制，这些机制似乎主要局限于延髓水平。该肽在脑桥中无作用，这与放射自显影研究证明的该水平呼吸相关核中不存在CCK受体一致。
